BLACK DIAMOND THERAPEUTICS, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2023-03-09
- BLACK DIAMOND THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2021-03-31 was $1.00K.
- BLACK DIAMOND THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2020-03-31 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- BLACK DIAMOND THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2021 was $10.00K, a 58.33% decline from fiscal 2020.
- BLACK DIAMOND THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2020 was $24.00K.
- BLACK DIAMOND THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2019 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-09 | |
| 2021-12-31 | $10.00K 10-K · filed 2023-03-09 | |
| 2021-03-31 | $1.00K 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $24.00K 10-K · filed 2022-03-17 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | |
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |